Irhythm Technologies Inc (NASDAQ:IRTC) saw some unusual options trading on Thursday. Investors purchased 815 put options on the company. This represents an increase of 906% compared to the average daily volume of 81 put options.

In related news, Director Raymond W. Scott sold 6,877 shares of the business’s stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $80.41, for a total value of $552,979.57. Following the transaction, the director now directly owns 8,905 shares of the company’s stock, valued at approximately $716,051.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Matthew C. Garrett sold 14,537 shares of the business’s stock in a transaction that occurred on Wednesday, July 18th. The stock was sold at an average price of $83.91, for a total value of $1,219,799.67. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 91,414 shares of company stock valued at $7,566,879. 23.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of IRTC. Cubist Systematic Strategies LLC purchased a new stake in shares of Irhythm Technologies during the 2nd quarter worth approximately $101,000. Mitsubishi UFJ Securities Holdings Co. Ltd. purchased a new stake in shares of Irhythm Technologies during the 2nd quarter worth approximately $140,000. SG Americas Securities LLC purchased a new stake in shares of Irhythm Technologies during the 1st quarter worth approximately $112,000. Great West Life Assurance Co. Can raised its holdings in shares of Irhythm Technologies by 119.9% during the 2nd quarter. Great West Life Assurance Co. Can now owns 1,979 shares of the company’s stock worth $161,000 after acquiring an additional 1,079 shares in the last quarter. Finally, United Services Automobile Association purchased a new stake in shares of Irhythm Technologies during the 2nd quarter worth approximately $242,000.

A number of research analysts recently commented on the company. ValuEngine raised Irhythm Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, May 9th. Canaccord Genuity reissued a “buy” rating and issued a $93.00 price target on shares of Irhythm Technologies in a report on Thursday, August 2nd. BidaskClub raised Irhythm Technologies from a “hold” rating to a “buy” rating in a report on Friday, July 6th. Dougherty & Co cut Irhythm Technologies from a “neutral” rating to a “sell” rating in a report on Monday, July 16th. Finally, Morgan Stanley boosted their price target on Irhythm Technologies from $86.00 to $92.00 and gave the stock an “overweight” rating in a report on Thursday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $84.29.

NASDAQ IRTC opened at $92.24 on Friday. The company has a quick ratio of 5.47, a current ratio of 5.58 and a debt-to-equity ratio of 0.48. Irhythm Technologies has a 12 month low of $45.19 and a 12 month high of $92.58.

Irhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings results on Wednesday, August 1st. The company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.12). Irhythm Technologies had a negative return on equity of 53.59% and a negative net margin of 34.38%. The business had revenue of $35.50 million during the quarter, compared to analysts’ expectations of $32.52 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The firm’s revenue for the quarter was up 48.8% on a year-over-year basis. equities research analysts predict that Irhythm Technologies will post -1.91 earnings per share for the current fiscal year.

About Irhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Further Reading: Market Capitalization – What it Means for Investors

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.